Pompholyx after IV immunoglobulin therapy for neurologic disease

Neurology

Volumn 54, Issue 9, 2000, Pages 1879-

  Iannaccone, S ^a   Sferrazza, B ^a   Quattrini, A ^a   Ferini Strambi, L ^a  

^a NONE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; CORTICOSTEROID; IMMUNOGLOBULIN G;

ADULT; CASE REPORT; DRUG EFFECT; ECZEMA; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOTHERAPY; LETTER; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL;

AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ECZEMA, DYSHIDROTIC; FEMALE; GUILLAIN-BARRE SYNDROME; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULIN G; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING; RECURRENCE;

EID: 0034624923     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: None     Document Type: Letter

References (3)

1. Iannaccone S, Sferrazza B, Quattrini A, Smirne S, Ferini-Strambi L. Pompholyx (vesicular eczema) after IV immunoglobulin therapy for neurologic disease. Neurology 1999; 53:1154-1155.
2. Sorensen PS, Wanscher B, Jensen CV, et al. Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology 1998; 50:1273-1281.
3. Hamdalla HHM, Hawkes CH, Spokes EG, Bamford JM, Goulding PJ. Intravenous immunoglobulin in the Guillain-Barré syndrome may cause severe adverse skin reactions. BMJ 1996; 313:1399-1400.